DKK1 and AL amyloidosis: Of the nine trials using Dkk1 neutralizing antibodies to activate Wnt signaling, six are treating Multiple Myeloma related cancers: three of the trials are by Leap Therapeutics using a proprietary DKK1 neutralizing antibody DKN-01; and three by Novartis Pharmaceuticals using the well-characterized DKK1 neutralizing antibody BHQ880.